PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –December 31, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Jan. 8, 2018-- Regulatory News : Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol : ERYP) &
View HTML
Toggle Summary Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –December 31, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Jan. 8, 2018-- Regulatory News : Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol : ERYP) &
View HTML
Toggle Summary ERYTECH to Present at the 2018 BIO CEO & Investor Conference
ERYTECH to Present at the 2018 BIO CEO & Investor Conference LYON, France - February 8, 2018 - ERYTECH Pharma (Euronext Paris: ERYP, Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today
View HTML
Toggle Summary ERYTECH to Present at the 2018 BIO CEO & Investor Conference
ERYTECH to Present at the 2018 BIO CEO & Investor Conference LYON, France - February 8, 2018 - ERYTECH Pharma (Euronext Paris: ERYP, Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today
View HTML
Toggle Summary Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – January 31, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Feb. 12, 2018-- Regulatory News : Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) &
View HTML
Toggle Summary Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – January 31, 2018
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Feb. 12, 2018-- Regulatory News : Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment B - ISIN Code: FR0011471135- Symbol : ERYP) &
View HTML
Toggle Summary ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase
ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase Set-up activities for Phase 2 clinical study ongoing and patient enrollment expected to start Q3 2018 LYON, France - February 13, 2018 - ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage
View HTML
Toggle Summary ERYTECH Selects Triple Negative Breast Cancer as Next Indication for Eryaspase
Set-up activities for Phase 2 clinical study ongoing and patient enrollment expected to start Q3 2018 LYON, France --(BUSINESS WIRE)--Feb. 13, 2018-- Regulatory News : ERYTECH Pharma (Euronext: ERYP- Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by
View HTML
Toggle Summary ERYTECH to Host Fourth Quarter and Full Year 2017 Conference Call and Business Update
LYON, France --(BUSINESS WIRE)--Mar. 6, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its
View HTML
Toggle Summary ERYTECH to Host Fourth Quarter and Full Year 2017 Conference Call and Business Update
LYON, France --(BUSINESS WIRE)--Mar. 6, 2018-- Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its
View HTML
Top